Comprehensive Analysis of Germline Variants in Mexican Patients with Hereditary Breast and Ovarian Cancer Susceptibility

Hereditary breast and ovarian cancer syndrome (HBOC) represents 5⁻10% of all patients with breast cancer and is associated with high-risk pathogenic alleles in genes, but only for 25% of cases. We aimed to find new pathogenic alleles in a panel of 143 cancer-predisposing genes in 300 Mexican cancer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2018-09, Vol.10 (10), p.361
Hauptverfasser: Quezada Urban, Rosalía, Díaz Velásquez, Clara Estela, Gitler, Rina, Rojo Castillo, María Patricia, Sirota Toporek, Max, Figueroa Morales, Andrea, Moreno García, Oscar, García Esquivel, Lizbeth, Torres Mejía, Gabriela, Dean, Michael, Delgado Enciso, Iván, Ochoa Díaz López, Héctor, Rodríguez León, Fernando, Jan, Virginia, Garzón Barrientos, Víctor Hugo, Ruiz Flores, Pablo, Espino Silva, Perla Karina, Haro Santa Cruz, Jorge, Martínez Gregorio, Héctor, Rojas Jiménez, Ernesto Arturo, Romero Cruz, Luis Enrique, Méndez Catalá, Claudia Fabiola, Álvarez Gómez, Rosa María, Fragoso Ontiveros, Verónica, Herrera, Luis Alonso, Romieu, Isabelle, Terrazas, Luis Ignacio, Chirino, Yolanda Irasema, Frecha, Cecilia, Oliver, Javier, Perdomo, Sandra, Vaca Paniagua, Felipe
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hereditary breast and ovarian cancer syndrome (HBOC) represents 5⁻10% of all patients with breast cancer and is associated with high-risk pathogenic alleles in genes, but only for 25% of cases. We aimed to find new pathogenic alleles in a panel of 143 cancer-predisposing genes in 300 Mexican cancer patients with suspicion of HBOC and 27 high-risk patients with a severe family history of cancer, using massive parallel sequencing. We found pathogenic variants in 23 genes, including . In the group of cancer patients 15% (46/300) had a pathogenic variant; 11% (33/300) harbored variants with unknown clinical significance (VUS) and 74% (221/300) were negative. The high-risk group had 22% (6/27) of patients with pathogenic variants, 4% (1/27) had VUS and 74% (20/27) were negative. The most recurrent mutations were the Mexican founder deletion of exons 9-12 and the variant p.G228fs in , each found in 5 of 17 patients with alterations in this gene. Rare VUS with potential impact at the protein level were found in 21 genes. Our results show for the first time in the Mexican population a higher contribution of pathogenic alleles in other susceptibility cancer genes (54%) than in (46%), highlighting the high locus heterogeneity of HBOC and the necessity of expanding genetic tests for this disease to include broader gene panels.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers10100361